DPP4 and type 2 diabetes mellitus: When added to on-going therapy with a thiazolidinedione in subjects with type 2 diabetes, the DPP-4 inhibitors were studied in 24–26 week placebo-controlled studies with a total number of 2,146 subjects [Table 2; (84–88)].